Paul Choi
Stock Analyst at Goldman Sachs
(2.24)
# 1,491
Out of 4,667 analysts
91
Total ratings
45.95%
Success rate
-3.71%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $180 → $200 | $124.38 | +60.80% | 3 | Sep 17, 2024 | |
| CYTK Cytokinetics | Downgrades: Neutral | $85 → $60 | $49.71 | +20.70% | 2 | Aug 13, 2024 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $12 | $8.73 | +37.46% | 7 | Aug 9, 2024 | |
| DVAX Dynavax Technologies | Maintains: Neutral | $20 → $15 | $12.20 | +22.95% | 2 | Aug 8, 2024 | |
| HCM HUTCHMED (China) | Maintains: Neutral | $17 → $19 | $17.82 | +6.62% | 6 | Aug 1, 2024 | |
| GOSS Gossamer Bio | Maintains: Buy | $8 | $0.70 | +1,048.60% | 4 | Jun 17, 2024 | |
| RGNX REGENXBIO | Initiates: Buy | $38 | $9.54 | +298.53% | 1 | Jun 7, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $18 → $32 | $41.96 | -23.74% | 6 | May 28, 2024 | |
| ARVN Arvinas | Initiates: Buy | $70 | $22.69 | +208.51% | 1 | Feb 1, 2024 | |
| URGN UroGen Pharma | Maintains: Neutral | $11 → $18 | $11.45 | +57.21% | 2 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $21.21 | +50.87% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $28 | $6.74 | +315.43% | 7 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $1.5 → $1 | $0.49 | +102.27% | 7 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $23.04 | +117.01% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $7.86 | +141.73% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.35 | +471.43% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $39.34 | +52.52% | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.57 | +1,492.36% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $3.5 → $3 | $2.41 | +24.48% | 7 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $4 | $0.94 | +325.89% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $46.83 | +263.02% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $2.84 | +181.69% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $18.46 | +78.76% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $37.44 | +199.15% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $123.29 | +9.50% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $1.00 | +1,900.00% | 2 | Mar 30, 2020 |
Ascendis Pharma
Sep 17, 2024
Maintains: Buy
Price Target: $180 → $200
Current: $124.38
Upside: +60.80%
Cytokinetics
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $49.71
Upside: +20.70%
Phathom Pharmaceuticals
Aug 9, 2024
Maintains: Neutral
Price Target: $10 → $12
Current: $8.73
Upside: +37.46%
Dynavax Technologies
Aug 8, 2024
Maintains: Neutral
Price Target: $20 → $15
Current: $12.20
Upside: +22.95%
HUTCHMED (China)
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $17.82
Upside: +6.62%
Gossamer Bio
Jun 17, 2024
Maintains: Buy
Price Target: $8
Current: $0.70
Upside: +1,048.60%
REGENXBIO
Jun 7, 2024
Initiates: Buy
Price Target: $38
Current: $9.54
Upside: +298.53%
PTC Therapeutics
May 28, 2024
Maintains: Sell
Price Target: $18 → $32
Current: $41.96
Upside: -23.74%
Arvinas
Feb 1, 2024
Initiates: Buy
Price Target: $70
Current: $22.69
Upside: +208.51%
UroGen Pharma
Jul 31, 2023
Maintains: Neutral
Price Target: $11 → $18
Current: $11.45
Upside: +57.21%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $21.21
Upside: +50.87%
Jul 21, 2023
Maintains: Buy
Price Target: $51 → $28
Current: $6.74
Upside: +315.43%
Jul 20, 2023
Maintains: Sell
Price Target: $1.5 → $1
Current: $0.49
Upside: +102.27%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $23.04
Upside: +117.01%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $7.86
Upside: +141.73%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.35
Upside: +471.43%
Dec 14, 2022
Initiates: Buy
Price Target: $60
Current: $39.34
Upside: +52.52%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.57
Upside: +1,492.36%
May 24, 2022
Maintains: Sell
Price Target: $3.5 → $3
Current: $2.41
Upside: +24.48%
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $0.94
Upside: +325.89%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $46.83
Upside: +263.02%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $2.84
Upside: +181.69%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $18.46
Upside: +78.76%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $37.44
Upside: +199.15%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $123.29
Upside: +9.50%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $1.00
Upside: +1,900.00%